We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Brainsway Ltd | NASDAQ:BWAY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.155 | 2.55% | 6.245 | 6.23 | 6.26 | 6.34 | 6.15 | 6.15 | 30,202 | 20:27:22 |
From Jun 2022 to Jun 2024
By Colin Kellaher
Shares of Brainsway Ltd. jumped more than 20% in premarket trading Monday after the maker of noninvasive neurostimulation treatments said it received Food and Drug Administration approval for the expanded use of its Deep TMS H7 coil for depression in adults.
The Jerusalem company said the approval covers adults with major depressive disorder and depression, including those with comorbid anxiety symptoms commonly known as anxious depression.
The H7 coil has been approved to treat obsessive-compulsive disorder since 2018.
Brainsway shares, which closed Friday at $4.50, were recently up nearly 22% to $5.47 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 29, 2022 08:41 ET (12:41 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Brainsway Chart |
1 Month Brainsway Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
